Ajanta Pharma (BOM:532331) Debt-to-Equity : 0.01 (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Ajanta Pharma Debt-to-Equity?

Ajanta Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹118 Mil. Ajanta Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹235 Mil. Ajanta Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹35,674 Mil. Ajanta Pharma's debt to equity for the quarter that ended in Mar. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Ajanta Pharma's Debt-to-Equity or its related term are showing as below:

BOM:532331' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.07
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of Ajanta Pharma was 0.07. The lowest was 0.00. And the median was 0.01.

BOM:532331's Debt-to-Equity is ranked better than
99.88% of 849 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs BOM:532331: 0.01

Ajanta Pharma Debt-to-Equity Historical Data

The historical data trend for Ajanta Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ajanta Pharma Debt-to-Equity Chart

Ajanta Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.01

Ajanta Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.01	N/A	0.01	N/A	0.01

Competitive Comparison of Ajanta Pharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Ajanta Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ajanta Pharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ajanta Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Ajanta Pharma's Debt-to-Equity falls into.

Ajanta Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Ajanta Pharma's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(117.6	+	235.2)	/	35673.6
	=	0.01

Ajanta Pharma's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(117.6	+	235.2)	/	35673.6
	=	0.01

Ajanta Pharma (BOM:532331) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Ajanta Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Ajanta Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Ajanta Pharma (BOM:532331) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ajanta Pharma Ltd (BOM:532331) » Definitions » Debt-to-Equity

Traded in Other Exchanges

AJANTPHARM:India

Address

Ajanta House, 98 Government Industrial Area, Charkop, Kandivli (West), Mumbai, MH, IND, 400 067

Website

https://www.ajantapharma.com

Ajanta Pharma Ltd is a drug manufacturing company with a focus on specialty pharmaceutical products. The company maintains a global presence while generating the vast majority of its revenue in Africa and India. Ajanta's strategy aims to successfully select molecules and products for development while enhancing its research and development capabilities. The company works to develop formulations in different dosages such as tablets, cream, capsules, liquid, and lotion. The company's manufacturing plants are located in India.

Ajanta Pharma (BOM:532331) Headlines

No Headlines